The Current Ratio as of September 2024 (TTM) for Tarsus Pharmaceuticals, Inc. (TARS) is 7.03

According to Tarsus Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 7.03. This represents a change of -15.11% compared to the average of 8.28 of the last 4 quarters.

Tarsus Pharmaceuticals, Inc. (TARS) Historical Current Ratio (quarterly & annually)

How has TARS Current Ratio performed in the past?

The mean historical Current Ratio of Tarsus Pharmaceuticals, Inc. over the last ten years is 25.45. The current 7.03 Current Ratio has changed 2.66% with respect to the historical average. Over the past ten years (40 quarters), TARS's Current Ratio was at its highest in in the December 2019 quarter at 70.85. The Current Ratio was at its lowest in in the March 2018 quarter at 0.

Tarsus Pharmaceuticals, Inc. (TARS) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Tarsus Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Tarsus Pharmaceuticals, Inc. (TARS) Average Current Ratio

How has TARS Current Ratio performed in the past?

The current Current Ratio of Tarsus Pharmaceuticals, Inc. (TARS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Tarsus Pharmaceuticals, Inc. (TARS) Current Ratio vs. Peers

How is TARS’s Current Ratio compared to its peers?

Tarsus Pharmaceuticals, Inc.’s Current Ratio is less than LianBio (10.06), greater than Aldeyra Therapeutics, Inc. (4.41), greater than Travere Therapeutics, Inc. (3.04), greater than Eton Pharmaceuticals, Inc. (1.40), greater than Connect Biopharma Holdings Limited (4.99), less than Acumen Pharmaceuticals, Inc. (17.37), less than Nuvation Bio Inc. (11.49), less than Eledon Pharmaceuticals, Inc. (14.48), greater than Opthea Limited (2.94), less than Centessa Pharmaceuticals plc (13.29), less than Nuvalent, Inc. (17.44), greater than Genfit S.A. (2.94), greater than Monte Rosa Therapeutics, Inc. (6.56), less than Design Therapeutics, Inc. (41.42), less than Werewolf Therapeutics, Inc. (12.13), less than Ikena Oncology, Inc. (18.22), greater than Stoke Therapeutics, Inc. (6.67), less than PepGen Inc. (7.45), less than Tyra Biosciences, Inc. (36.46), greater than Entrada Therapeutics, Inc. (5.70), less than Pharvaris N.V. (18.45), less than Rallybio Corporation (7.52),

Build a custom stock screener for Tarsus Pharmaceuticals, Inc. (TARS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Tarsus Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Tarsus Pharmaceuticals, Inc. (TARS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Tarsus Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.